Does the media refer more to OCUL or IBRX?

In the previous week, ImmunityBio had 3 more articles in the media than Ocular Therapeutix. MarketBeat recorded 12 mentions for ImmunityBio and 9 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.65 beat ImmunityBio's score of 0.57 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCUL or RYTM?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 9 mentions for Ocular Therapeutix. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat Ocular Therapeutix's score of 0.65 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or OCUL?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 9 mentions for Ocular Therapeutix. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Ocular Therapeutix's score of 0.65 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LNTH or OCUL?

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.21 $233.56M $4.15 24.01 Ocular Therapeutix $51.95M 34.44 -$265.94M -$1.46 N/A

Does the media prefer LNTH or OCUL?

In the previous week, Lantheus had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Lantheus and 9 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.65 beat Lantheus' score of 0.33 indicating that Ocular Therapeutix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OCUL or COGT?

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 9 articles in the media. Cogent Biosciences' average media sentiment score of 1.53 beat Ocular Therapeutix's score of 0.65 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Ocular Therapeutix (OCUL) Competitors

$8.17 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$8.18 +0.01 (+0.06%)

As of 07/31/2026 07:50 PM Eastern

Compare

OCUL vs. IBRX, RYTM, MIRM, LNTH, and COGT

Should you buy Ocular Therapeutix stock or one of its competitors? MarketBeat compares Ocular Therapeutix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocular Therapeutix include ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Cogent Biosciences (COGT).

How does Ocular Therapeutix compare to ImmunityBio?

Ocular Therapeutix (NASDAQ:OCUL) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Ocular Therapeutix currently has a consensus price target of $25.11, suggesting a potential upside of 207.36%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 98.05%. Given Ocular Therapeutix's higher probable upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, ImmunityBio had 3 more articles in the media than Ocular Therapeutix. MarketBeat recorded 12 mentions for ImmunityBio and 9 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.65 beat ImmunityBio's score of 0.57 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ocular Therapeutix has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A
ImmunityBio	$113.29M	66.29	-$351.40M	-$0.85	N/A

Ocular Therapeutix has a net margin of -558.24% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
ImmunityBio	-606.15%	N/A	-59.53%

Ocular Therapeutix has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market.

Summary

Ocular Therapeutix beats ImmunityBio on 9 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Rhythm Pharmaceuticals?

Ocular Therapeutix (NASDAQ:OCUL) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Ocular Therapeutix currently has a consensus price target of $25.11, indicating a potential upside of 207.36%. Rhythm Pharmaceuticals has a consensus price target of $138.73, indicating a potential upside of 39.78%. Given Ocular Therapeutix's higher probable upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Rhythm Pharmaceuticals and 9 mentions for Ocular Therapeutix. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat Ocular Therapeutix's score of 0.65 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A
Rhythm Pharmaceuticals	$189.76M	35.84	-$196.54M	-$3.13	N/A

59.2% of Ocular Therapeutix shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Summary

Rhythm Pharmaceuticals beats Ocular Therapeutix on 11 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Ocular Therapeutix's net margin of -558.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Mirum Pharmaceuticals currently has a consensus target price of $143.40, indicating a potential upside of 35.35%. Ocular Therapeutix has a consensus target price of $25.11, indicating a potential upside of 207.36%. Given Ocular Therapeutix's higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71

59.2% of Ocular Therapeutix shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	11.34	-$23.36M	-$13.61	N/A
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 10 mentions for Mirum Pharmaceuticals and 9 mentions for Ocular Therapeutix. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Ocular Therapeutix's score of 0.65 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

In the previous week, Lantheus had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 14 mentions for Lantheus and 9 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.65 beat Lantheus' score of 0.33 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus presently has a consensus price target of $109.71, indicating a potential upside of 10.11%. Ocular Therapeutix has a consensus price target of $25.11, indicating a potential upside of 207.36%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Ocular Therapeutix's net margin of -558.24%. Lantheus' return on equity of 29.32% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.21	$233.56M	$4.15	24.01
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A

Summary

Lantheus beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Cogent Biosciences?

Ocular Therapeutix (NASDAQ:OCUL) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Cogent Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Cogent Biosciences	N/A	-104.27%	-54.64%

Ocular Therapeutix has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Ocular Therapeutix presently has a consensus target price of $25.11, indicating a potential upside of 207.36%. Cogent Biosciences has a consensus target price of $45.90, indicating a potential upside of 17.90%. Given Ocular Therapeutix's higher probable upside, research analysts plainly believe Ocular Therapeutix is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ocular Therapeutix has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	34.44	-$265.94M	-$1.46	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Ocular Therapeutix and Ocular Therapeutix both had 9 articles in the media. Cogent Biosciences' average media sentiment score of 1.53 beat Ocular Therapeutix's score of 0.65 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Ocular Therapeutix beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.79B	$11.71B	$6.86B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-5.60	799.05	282.30	24.66
Price / Sales	34.44	751.29	564.98	76.51
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	2.66	10.36	10.92	6.07
Net Income	-$265.94M	$2.82B	$3.49B	$347.99M
7 Day Performance	-5.44%	-0.13%	-0.64%	-0.44%
1 Month Performance	-15.25%	-3.99%	-5.24%	-4.81%
1 Year Performance	-31.46%	156.16%	61.98%	18.61%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	2.7548 of 5 stars	$8.17 flat	$25.11 +207.4%	-31.5%	$1.79B	$51.95M	N/A	230	Upcoming Earnings Gap Up
IBRX ImmunityBio	2.5511 of 5 stars	$6.99 -1.5%	$14.20 +103.1%	+202.5%	$7.44B	$113.29M	N/A	590	Upcoming Earnings Gap Up
RYTM Rhythm Pharmaceuticals	3.4024 of 5 stars	$106.13 +3.9%	$138.73 +30.7%	+12.4%	$7.00B	$189.76M	N/A	140	Positive News Upcoming Earnings Gap Up
MIRM Mirum Pharmaceuticals	3.3361 of 5 stars	$114.20 +1.0%	$143.40 +25.6%	+103.7%	$6.89B	$569.61M	N/A	140	Positive News Upcoming Earnings Gap Up
LNTH Lantheus	3.1989 of 5 stars	$108.03 +3.1%	$110.43 +2.2%	+41.2%	$6.82B	$1.54B	26.03	1,193	Positive News Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. IBRX, RYTM, MIRM, LNTH, and COGT

How does Ocular Therapeutix compare to ImmunityBio?

Summary

How does Ocular Therapeutix compare to Rhythm Pharmaceuticals?

Summary

How does Ocular Therapeutix compare to Mirum Pharmaceuticals?

Summary

How does Ocular Therapeutix compare to Lantheus?

Summary

How does Ocular Therapeutix compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. IBRX, RYTM, MIRM, LNTH, and COGT

How does Ocular Therapeutix compare to ImmunityBio?

Do analysts recommend OCUL or IBRX?

Does the media refer more to OCUL or IBRX?

Do insiders and institutionals hold more shares of OCUL or IBRX?

Which has higher earnings and valuation, OCUL or IBRX?

Is OCUL or IBRX more profitable?

Which has more risk & volatility, OCUL or IBRX?

Summary

How does Ocular Therapeutix compare to Rhythm Pharmaceuticals?

Which has more risk & volatility, OCUL or RYTM?

Do analysts rate OCUL or RYTM?

Does the media favor OCUL or RYTM?

Which has preferable earnings & valuation, OCUL or RYTM?

Do insiders & institutionals have more ownership in OCUL or RYTM?

Is OCUL or RYTM more profitable?

Summary

How does Ocular Therapeutix compare to Mirum Pharmaceuticals?

Is MIRM or OCUL more profitable?

Do analysts prefer MIRM or OCUL?

Do insiders and institutionals believe in MIRM or OCUL?

Which has more volatility and risk, MIRM or OCUL?

Which has preferable valuation and earnings, MIRM or OCUL?

Does the media favor MIRM or OCUL?

Summary

How does Ocular Therapeutix compare to Lantheus?

Which has more risk & volatility, LNTH or OCUL?

Does the media prefer LNTH or OCUL?

Do analysts prefer LNTH or OCUL?

Do institutionals & insiders have more ownership in LNTH or OCUL?

Is LNTH or OCUL more profitable?

Which has higher earnings & valuation, LNTH or OCUL?

Summary

How does Ocular Therapeutix compare to Cogent Biosciences?

Is OCUL or COGT more profitable?

Which has more risk and volatility, OCUL or COGT?

Do analysts prefer OCUL or COGT?

Do institutionals and insiders believe in OCUL or COGT?

Which has better valuation & earnings, OCUL or COGT?

Does the media favor OCUL or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools